The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 21 of the 32 sources its claims cite were checked for support.
Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial
Open accessAbstract
BACKGROUND: A dysbiotic vaginal microbiome (VMB) is associated with clinical conditions such as bacterial vaginosis (BV) and an increased risk of human immunodeficiency virus (HIV-1) infection. Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility. METHODS: ACB women aged 18-49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. Feasibility was evaluated through enrolment, retention, and adherence rates, while safety and tolerability were determined by a pre- and post-treatment blood panel and reported adverse events (AEs). RESULTS: Overall, 63 ACB women were screened, 50 were enrolled and received the intervention while 41 completed the study, resulting in 80% enrollment and 82% retention rates. Overall adherence to the study protocol was high at 93%, with an adherence of 92% for RepHresh™ Pro-B™ and 97% for Estring©. A total of 88 AEs were reported by 29 participants which were mild (66/88; 75%) and largely resolved (82/88;93%) by the end of the study, with no serious AEs (SAEs) noted. In addition, a panel of safety blood markers measured pre- and post-intervention confirmed no clinically significant changes in blood chemistry or blood cell count. CONCLUSION: Overall, the administration of intravaginal estrogen and/or probiotics in pre-menopausal ACB women is feasible, safe, and well tolerated. TRIAL REGISTRATION: The trial was registered with Clinicaltrials.gov (NCT03837015) and CIHR HIV Clinical Trials (CTN308).
Overview
CoChat Summary
## TL;DR
This phase 1 randomized open-label trial in healthy premenopausal Canadian African, Caribbean, and Black (ACB) women found that 30 days of intravaginal estradiol and/or probiotics was feasible, safe, and well tolerated. Across 50 treated participants, enrollment was 80%, retention was 82%, adherence was 93%, and no serious adverse events or clinically significant blood-marker changes were seen.
## Key findings
- Of 63 screened women, 50 were enrolled/treated and 41 completed the study, yielding an 80% enrollment rate and 82% retention rate; these met or exceeded the prespecified feasibility targets of 70% and 80%, respectively.
- Overall adherence was 93% (probiotic adherence 92%; Estring adherence 97%); diary completion was 97% when including participants who discontinued, and sexual history questionnaire completion was 100%.
- A total of 88 adverse events were reported by 29 participants; 66/88 (75%) were mild, 82/88 (93%) had resolved by study end, and no serious adverse events were reported.
- Pre- vs post-intervention blood panels showed no clinically significant changes in blood chemistry, complete blood count, lipids, or immune-cell markers.
## Methods
- Prospective, randomized, open-label, phase 1 clinical trial conducted over 30 days in healthy premenopausal ACB women aged 18–49 recruited from the Greater Toronto Area between Nov 1, 2019 and Dec 31, 2021.
- Participants were randomized 1:1:1:1 to intravaginal estradiol (Estring, 7.5 mg/day), vaginal probiotic twice daily, Estring plus vaginal probiotic, or Estring plus oral probiotic; 50 participants formed the intention-to-treat sample.
- Main analysis used descriptive statistics plus paired t-tests/Wilcoxon signed-rank tests for within-group changes and ANOVA/Kruskal-Wallis tests for between-group comparisons; safety was assessed using pre/post blood markers and reported adverse events.
## Limitations
- The paper states that the sample size was small and that generalizability is constrained by this pilot phase 1 design.
- The paper states that adherence was based mainly on self-report diaries and returned products, which does not rule out false reporting.
- The paper states that there was no placebo arm and that the pre/post design could be confounded by factors such as diet or seasonal changes.
- Evident from the text: participants were self-referred, so selection bias is possible.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
8 Valid · 1 Not valid · 2 Not checked · 21 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A recent study of vaginally administered biotherapeutic Lactobacillus crispatus CTV-05 strain LACTIN-V, demonstrated reduced BV recurrence at 24 weeks from 54% to 39% [31].”
§ Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial > Introduction
What the sources say
- Partly supportedcites [31] CR Cohen, 2020, Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis, N Engl J Med sourceExperimental — accuracy not yet measured
The Methods describe vaginally administered Lactin-V, and the Abstract Results report a lower risk of BV recurrence by week 24 than with placebo (risk ratio 0.73). The passages in our copy do not give the claimed week-24 recurrence rates of 54% and 39%, so those exact percentages cannot be verified. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Vaginal irritation/burning/itching (20/88;22%), abdominal pain/cramps (12/88;14%), and headache (11/88; 12%) were the most reported AEs (Fig 4).”
§ Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial > Results > Safety and tolerability outcomes
plainn = 37- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 88 AEs were reported by 37 participants who used each intervention across the four study groups (S1 Table in S1 File).”
§ Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial > Results > Safety and tolerability outcomes
plainn = 37- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The data obtained before and after the 30 days of intervention demonstrated no clinically significant changes in metabolite, lipid and complete blood count panels (Fig 5).”
§ Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial > Results > Safety and tolerability outcomes
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The high adherence to the study protocol indicates that all the intervention types and routes of probiotic administration are acceptable.”
§ Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial > Discussion
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
2 more claims
Create a free account to see all 32 claims and to verify the 2 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial > Results > Safety and tolerability outcomes
“A total of 88 AEs were reported by 37 participants who used each intervention across the four study groups (S1 Table in S1 File).”
§ Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial > Abstract > Results
“A total of 88 AEs were reported by 29 participants which were mild (66/88; 75%) and largely resolved (82/88;93%) by the end of the study, with no serious AEs (SAEs) noted.”
Citations
Cites
Registries for Evaluating Patient Outcomes: A User’s Guide
(2020) · doi:10.23970/ahrqepcregistries4 · Cited by 960
The Vaginal Microenvironment: The Physiologic Role of Lactobacilli
Amabebe, E., & Anumba, D. O. C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00181 · Cited by 785 · cited 3×
“While the Estring © has not been used in premenopausal women, both topical estrogen creams and vaginal rings containing estrogen have been employed safely in post-menopausal women and are well-tolerated [5, 43].”
Bacterial vaginosis and HIV acquisition: A meta-analysis of published studies
Atashili, J., Poole, C., Ndumbe, P. M., Adimora, A. A., & Smith, J. S. (2008) · AIDS · doi:10.1097/qad.0b013e3283021a37 · Cited by 706
Gosmann, C., Anahtar, M. N., Handley, S. A., Farcasanu, M., Abu-Ali, G., Bowman, B. A., Padavattan, N., Desai, C., Droit, L., Moodley, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2016.12.013 · Cited by 696
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis
Cohen, C. R., Wierzbicki, M. R., French, A. L., Morris, S., Newmann, S., Reno, H., Green, L., Miller, S., Powell, J., Parks, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915254 · Cited by 377 · cited 4×
“A recent study of vaginally administered biotherapeutic Lactobacillus crispatus CTV-05 strain LACTIN-V, demonstrated reduced BV recurrence at 24 weeks from 54% to 39% [31].”
InfluentialEriksen, B. C. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70597-1 · Cited by 336 · cited 2×
“While the Estring © has not been used in premenopausal women, both topical estrogen creams and vaginal rings containing estrogen have been employed safely in post-menopausal women and are well-tolerated [5, 43].”
Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora
Reid, G., Beuerman, D., Heinemann, C., & Bruce, A. W. (2001) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2001.tb00531.x · Cited by 328 · cited 3×
“The RepHresh ™ Pro-B ™ is a patented probiotic feminine supplement containing 1x10 9 cfu total of L . rhamnosus GR-1 and L . reuteri RC-14 per capsule [27].”
Self-citationAnukam, K., Osazuwa, E., Ahonkhai, I., Ngwu, M., Osemene, G., Bruce, A. W., & Reid, G. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.01.003 · Cited by 300 · cited 1×
“Consistent with the safety profile of Lactobacillus -based probiotics including those reported specifically for L . rhamnosus GR-1 and L . reuteri RC-14, the most common local side effects were cramps/abdominal pain and vaginal discomfort which were mild and infrequent [25, 30, 31, 34, 50].”
Self-citationAnukam, K. C., Osazuwa, E., Osemene, G. I., Ehigiagbe, F., Bruce, A. W., & Reid, G. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.08.008 · Cited by 276
Self-citation
Research works printed but not linked: 1
- MR Orazov, 2020, Combination local therapy for genitourinary syndrome of menopause: treatment perspectives, Gyn and Rep End & Metab, 1, 113
Cited by
Barski, D., Finzer, P., Golka, K., Renner, O., Wirtz, R. M., Ecke, T., & Otto, T. (2025) · Bioengineering · doi:10.3390/bioengineering12111134 · Cited by 3
“Recent pilot/feasibility trials report safety and suggestive benefit but are underpowered for definitive clinical endpoints [13,14].”
The female microbiome in HIV prevention, pathogenesis, and treatment
Peters, B. A., Usyk, M., & Burk, R. D. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000986 · Cited by 2
Wang, X., Zhou, L., Yu, X., Hou, Q., Wang, C., Cui, W., Hu, Y., Wang, X., & Zhu, Z. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1731528 · Cited by 4
Dabee, S., Niazy, M., Gill, B., Wessels, J. M., Hayes, C. L., Nazli, A., Ratcliffe, J., Wokuri, J., Reid, G., Kaul, R., et al. (2025) · medRxiv · doi:10.64898/2025.12.03.25341486
Self-citationBurkova, A. A., Galyavieva, R. I., Idrisova, L. V., Meryasova, G. F., Petrosyan, M. A., Rakhmatullina, D. I., Fatkhelislamova, E. I., Khaziev, I. R., Chernyavsky, M. A., Shaydullina, D. I., et al. (2026) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2026.773
Metadata
- Authors
- Gill, B., Wessels, J. M., Hayes, C. L., Ratcliffe, J., Wokuri, J., Ball, E., Reid, G., Kaul, R., Rana, J., Alkhaifi, M., Tharao, W., Smaill, F., & Kaushic, C.
- Affiliations
- McMaster University (CA)
- Women's Health In Women's Hands (CA)
- Western University (CA)
- University Health Network (CA)
- Michael G. DeGroote Institute for Infectious Disease Research (CA)
- Corresponding author
- Smaill, Fiona
- Kaushic, Charu
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2025-01-21
- Volume
- 20
- Issue
- 1
- Pages
- e0315576
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC11750099
- OpenAlex
- W4406657430
- Cited by
- 5
- References
- 61
- Citations by year
- 2026: 2 · 2025: 3
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Canadian Institutes of Health Research (FRN#181875, FRN#154047, FRN#159229)
- CIHR HIV Clinical Trials Network
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- estradiol, vaginal probiotics, vaginal microbiota, bacterial vaginosis, HIV-1 susceptibility, premenopausal women, feasibility and safety, student retention, adverse events, HIV prevention
- MeSH terms
- Caribbean People, Administration, Intravaginal, Adolescent, Adult, Canada, Estrogens, Feasibility Studies, Female, Humans, Middle Aged, Pilot Projects, Vagina, HIV Infections, Vaginosis, Bacterial, Probiotics, Black People, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial. https://app.cochat.ai/papers/10.1371/journal.pone.0315576
- The paper
- Gill, B., Wessels, J. M., Hayes, C. L., Ratcliffe, J., Wokuri, J., Ball, E., Reid, G., Kaul, R., Rana, J., Alkhaifi, M., Tharao, W., Smaill, F., & Kaushic, C. (2025). Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial. PLoS ONE. https://doi.org/10.1371/journal.pone.0315576
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.